18233-24-4

Usage

Uses

Used in Chemical Research:
2-(5-phenyl-1,3,4-oxadiazol-2-yl)phenol is used as a research compound for exploring its chemical properties and reactivity. Its distinctive structure makes it a candidate for various applications in the field of organic chemistry.
Used in Pharmaceutical Development:
2-(5-phenyl-1,3,4-oxadiazol-2-yl)phenol is used as a potential pharmaceutical agent due to its unique chemical structure. 2-(5-phenyl-1,3,4-oxadiazol-2-yl)phenol is under investigation for its possible therapeutic applications, which may include its use in drug design and development.
Used in Material Science:
In the field of material science, 2-(5-phenyl-1,3,4-oxadiazol-2-yl)phenol is used as a component in the synthesis of new materials. Its properties may contribute to the development of advanced materials with specific characteristics for various applications.
Used in Analytical Chemistry:
2-(5-phenyl-1,3,4-oxadiazol-2-yl)phenol is used as an analytical reagent in chemical analysis. Its distinctive structure may offer new ways to detect or quantify certain substances in complex mixtures.

InChI:InChI=1/C14H10N2O2/c17-12-9-5-4-8-11(12)14-16-15-13(18-14)10-6-2-1-3-7-10/h1-9,16H/b14-11+

Upstream product

• 41697-19-2 2-Benzoyl-1-(o-hydroxybenzoyl)hydrazine 
• 613-94-5 benzoic acid hydrazide 
• 63218-91-7 1-[(2-Hydroxy-phenyl)-methylsulfanyl-methylene]-piperidinium; iodide 
• 936-02-7 2-Hydroxybenzoylhydrazine 
• 98-07-7 Benzotrichlorid 
• 69-72-7 salicylic acid 
• 65-85-0 benzoic acid 
• 15563-40-3 N-thiobenzoylpiperidine 
• 98-88-4 benzoyl chloride 
• 6781-63-1 1-benzoyl-2-(2-methoxybenzoyl)hydrazine 
• 21615-34-9 2-Methoxybenzoyl chloride 
• 59395-02-7 N'-benzylidene-2-hydroxybenzohydrazide 
• 1874-42-6 2-[2-(methyloxyl)phenyl]-5-phenyl-1,3,4-oxadiazole 
• 111997-46-7 N²-(α-Morpholinobenzylidene)salicylohydrazide 

Downstream Products

• 1542992-98-2 C₃₈H₂₃F₆IrN₄O₂ 
• 1642111-06-5 2-(5-phenyl-1,3,4-oxadiazol-2-yl)phenol potassium salt 
• 1523272-57-2 2-(5-phenyl-1,3,4-oxadiazol-2-yl)phenyl benzoate 

Relevant academic research and scientific papers

Phosphorescence color tuning of oxadiazole-based iridium(III) complexes for organic light emitting diode

The new heteroleptic iridium complexes bearing 2-(5-phenyl-1,3,4-oxadiazol- 2-yl)phenolate (ODZ), were synthesized and characterized for application to organic light-emitting diodes (OLEDs). As main ligands (C^N), the anions of 2-phenylpyridine

Catalytic application of electrochemically prepared nickel oxide nanoparticles to synthesize 2, 5–disubstituted-1,3,4–oxadiazoles

The present work aims to synthesize 2,5–disubstituted-1,3,4–oxadiazoles using electrochemically prepared nanoparticles of nickel oxide as catalyst.The nanoparticles thus prepared using electrochemical syntheses are in appreciable yield.The tetrabutyl phosphonium bromide has been used for capping followed by UV, FTIR, XRD, SEM EDS andTEM SAED studies for the characterization. The 2,5-disubstituted-1,3,4-oxadiazoles were synthesized from substituted benzoic acids and their hydrazides in microwave synthesis system using prepared nanoparticles as a catalyst.

Efficient green photoluminescence and electroluminescence of iridium complexes with high electron mobility

Aiming to balance the injection and transport of electrons and holes, nitrogen heterocycle and 1,3,4-oxadiazole derivatives were introduced in iridium(iii) complexes to obtain organic light-emitting diodes (OLEDs) with high performances. Thus, two novel Ir(iii) complexes (Ir(tfmphpm)2(pop) and Ir(tfmppm)2(pop)) with green emissions using 2-(3,5-bis(trifluoromethyl)phenyl)pyrimidine (tfmphpm) and 2-(2,6-bis(trifluoromethyl)pyridin-4-yl)pyrimidine (tfmppm) as cyclometalating ligands, and 2-(5-phenyl-1,3,4-oxadiazol-2-yl)phenol (pop) as an ancillary ligand were synthesized. Both emitters show high photoluminescence efficiencies up to 94% and good electron mobility. The devices using two emitters with the structure of ITO (indium-tin-oxide)/MoO3 (molybdenum oxide, 5 nm)/TAPC (di-[4-(N,N-ditolyl-amino)-phenyl]cyclohexane, 30 nm)/mCP (1,3-bis(9H-carbazol-9-yl)benzene, 5 nm)/Ir(iii) complexes (6 wt%):PPO21 (3-(diphenylphosphoryl)-9-(4-(diphenylphosphoryl)phenyl)-9H-carbazole, 10 nm)/TmPyPB (1,3,5-tri(m-pyrid-3-yl-phenyl) benzene, 40 nm)/LiF (1 nm)/Al (100 nm) display good electroluminescence performances with a maximum luminance of 48981 cd m2, a maximum current efficiency of 92.79 cd A1 and a maximum external quantum efficiency up to 31.8%, respectively, and the efficiency roll-off ratio is low, suggesting that they have potential application in OLEDs.

Orange red iridium complexes with good electron mobility and mild OLED efficiency roll-off

Two iridium(III) complexes with 1-(3,5-bis(trifluoromethyl)-pyridin-4-yl)isoquinoline (tntpiq) as main ligand, 2-(5-pyridin-4-yl)-1,3,4-oxadiazol-2-yl)phenol (pop) and 2-(5-pyridin-4-yl)-1,3,4-thiadiazol-2-yl)phenol (psp) as ancillary ligands were investigated. Both complexes emit orange red lights with different photoluminescence efficiencies (Ir(tntpiq)2(pop): λem = 585 nm, Φ = 0.41 and Ir(tntpiq)2(psp): λem = 590 nm, Φ = 0.59). Moreover, the electron mobility values of the two complexes are higher than that of the electron transport material Alq3 (tris(8-hydroxyquinoline)aluminium), which are beneficial for their performances in organic light-emitting diodes (OLEDs). The devices with a structure of ITO/MoO3 (3 nm)/TAPC (1,1-bis[4-[N,N-di(p-tolyl)amino]pyridin-4-yl]cyclohexane, 30 nm)/Ir(III) complexes (2 wt%): 26DCzPPy (2,6-bis(3-(carbazol-9-yl)pyridin-4-yl)pyridine, 10 nm)/TmPyPB (1,3,5-tri(m-pyrid-3-yl-pyridin-4-yl)benzene, 40 nm)/LiF (1 nm)/Al (100 nm) displayed similar performances with a maximum current efficiency of 24.3 cd A?1 and a maximum external quantum efficiency of 11.6%, respectively, and the efficiency roll-off is very mild.

Efficient Electroluminescence of Two Heteroleptic Platinum Complexes with a 2-(5-Phenyl-1,3,4-oxadiazol-2-yl)phenol Ancillary Ligand

Two new platinum(II) cyclometalated complexes with 2-phenylpyridine (Pt1) and 2-(4-trifluoromethyl)phenylpyridine (Pt2) as the main ligands and 2-(5-phenyl-1,3,4-oxadiazol-2-yl)phenol (pop) as the electron-transporting ancillary ligand were developed. The photoluminescence quantum efficiency yields of both green Pt1 and Pt2 phosphors (λmax 490 and 496 nm) are 20.0% and 31.0% in CH2Cl2 solutions, respectively. Efficient OLEDs (organic light emitting diodes) of ITO/TAPC (bis[4-(N,N-ditolylamino)phenyl]cyclohexane, 40 nm)/Pt1 or Pt2 (5 wt %):TCTA (4,4′,4″-tri(carbazoyl-9-yl)triphenylamine, 10 nm)/Pt1 or Pt2 (5 wt %):2,6DCzPPy (2,6-bis(3-(carbazol-9-yl)phenyl)pyridine, 10 nm)/TmPyPB (1,3,5-tris(m-pyrid-3-ylphenyl)benzene, 40 nm)/LiF (1 nm)/Al (100 nm) were fabricated. Particularly, device G1 based on complex Pt1 with 5 wt % doped concentration showed superior performance with a maximum current efficiency (ηmax,c) of 55.6 cd A-1, a maximum power efficiency (ηmax,p) of 52.2 lm W-1, and a maximum external quantum efficiency (EQEmax) of 18.0%. Device G2 with the Pt2 emitter displayed lower efficiency rolloff with ηc values of 48.5 and 43.1 cd A-1 as the luminance reached 5000 and 10000 cd m-2, respectively. These research results demonstrate that the Pt(II) complexes with an ancillary ligand attached with the 1,3,4-oxadiazole group have promising applications in efficient OLEDs.

Synthesis and antioxidant activity of 1,3,4-oxadiazoles and their diacylhydrazine precursors derived from phenolic acids

Eight 1,3,4-oxadiazole derivatives containing phenolic acid moieties (7a-h) and eight of their diacylhydrazine precursors (6a-h) were synthesized, characterized using spectroscopic methods and examined by scavenging of stable DPPH (2,2-diphenyl-1-picrylhydrazyl) radicals. The most potent phenolic 1,3,4-oxadiazoles showed better DPPH scavenging activity in comparison with their corresponding diacylhydrazine precursors as a result of participation of both aromatic rings and a 1,3,4-oxadiazole moiety in resonance stabilization of the formed phenoxyl radical. Four diacylhydrazines (6d, 6e, 6g, and 6h) and four 1,3,4-oxadiazoles (7d, 7e, 7g and 7h) with the best DPPH scavenging activity, were chosen for further evaluation of their antioxidant potential through various assays. The investigated compounds exerted pronounced ABTS radical scavenging capacity, moderate to good H2O2 scavenging properties and strong ferric ion reducing capacity. Further in vitro evaluation of the antioxidant properties of the most active compounds demonstrated their protective effects in normal lung fibroblasts MRC-5 against hydrogen peroxide induced oxidative stress. Diacylhydrazine 6h increased two times the activity of glutathione peroxidase in treated cells in comparison with a control sample and did not affect the superoxide dismutase activity.

Application of compound in preparation of kallikrein KLK7 inhibition medicines, and synthesis method of compound

The invention belongs to the field of biomedicines, and especially relates to an application of a compound in the preparation of kallikrein KLK7 inhibition medicines, and a synthesis method of the compound. The structural formula of the compound is shown in the description. The compound for inhibiting the kallikrein KLK7 can effectively inhibit the activity of the KLK7, the synthesis method of the compound is simple and is easy to implement, and proper auxiliary materials and assistants can be added to prepare medicinal preparations for inhibiting the activity of the KLK7.

Application of compound to preparation of medicine for inhibiting kallikrein KLK7 and synthesis method of compound

The invention belongs to the field of biomedicine and particularly relates to application of a compound to preparation of a medicine for inhibiting kallikrein KLK7 and a synthesis method of the compound. The compound is used for preparing the medicine for inhibiting kallikrein KLK7. The structural formula of the compound is as shown in the description. The compound for inhibiting kallikrein KLK7 can effectively inhibit the activity of KLK7, the synthesis method is easy to implement, and proper auxiliary materials and assistant are added so that the compound can be prepared into medicine preparations for inhibiting the activity of KLK7.

Application and synthetic method of compound in the preparation of a medicine for inhibiting kallikrein KLK7

The invention belongs to the field of biomedicine, and in particular to application and synthetic method of a compound in the preparation of a medicine for inhibiting kallikrein KLK7. The invention provides application of a compound in the preparation of a medicine for inhibiting kallikrein KLK7. The structural formula of the compound is shown as below. The compound for inhibiting kallikrein KLK7 release can effectively inhibit the KLK7 activity. The synthesis method is simple and easy; and suitable excipients and additives can be added to prepare a medicament preparation for inhibiting the activity of KLK7.

Application of compound in preparing medicine for inhibiting kallikrein (KLK7) and synthetic method of compound

The invention belongs to the field of biomedicine, and particularly relates to application of a compound in preparing medicine for inhibiting kallikrein (KLK7) and a synthetic method of the compound. According to the application of the compound in preparing medicine for inhibiting KLK7, the structural formula of the compound is shown in the description. The compound for inhibiting KLK7 can effectively inhibit the activity of KLK7; the synthetic method of the compound is simple and easy to implement, and the compound can be prepared into a pharmaceutical preparation for inhibiting the activity of KLK7 by adding proper accessories and auxiliaries.